Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)|
|Description||Researchers at St. Jude Children’s Research Hospital have discovered analogs of two bacterial natural products, FR901464 and pladienolide, known for their selective and potent in vivo anti-cancer activity. The analogs, designated sudemycins, are made synthetically and have similar anti-cancer activity but improved solubility and stability. They also have the potential to be developed into targeted anticancer drugs useful in treating cancer and disorders associated with pre-mRNA splicing dysregulation. Multiple lead compounds show real potential for the treatment of multiple cancers including certain subtypes of melanoma, leukemia, glioblastoma, and many others.|
|Keywords||sudemycin, pladienolide, cancer, natural product analogs|
|Granted Patents or Published Applications||US Patent Application Pending, published July 21, 2011 as U.S. 2011-0178098|
|Related Scientific References||Convertini P. et al., “Sudemycin E influences alternative splicing and changes chromatin modifications,” Nucleic Acids Res. (2014, Mar 11) Lagisetti, C. et al., “Optimization of antitumor modulators of pre-mRNA splicing,” J Med Chem. (2013) Lagisetti, C. et al., “Antitumor Compounds Based on a Natural Product Consensus Pharmacophore”, J. Med. Chem. (2008)|
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: April 2014